Lonza has started up the mid-scale manufacturing assets at its API facility in Nansha in China’s Guangdong province. The site is fully integrated within Lonza’s global small molecules manufacturing network and this expansion has increased employee numbers there by 70 to around 330.

Lonza has completed an expansion at its API manufacturing site at Nansha, China, as part of its recent investment to expand mid-scale capacity there. This focused on extending the capabilities and capacity of development laboratories and kilo-scale cGMP manufacturing laboratories for clinical supply of HPAPIs.